Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.710 +1.690 (+28.07%)
Streaming Delayed Price Updated: 12:16 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering
From D. Boral Capital
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
What's Going On With ImmunityBio Shares Wednesday? ↗
ImmunityBio shares are trading lower on Wednesday following the announcement of pricing details for its recent $100 million share offering. 
Via Benzinga
News headline image
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗
 
Via Benzinga
News headline image
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
From ImmunityBio, Inc.
Via Business Wire
News headline image
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
From ImmunityBio, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio Reports Third-Quarter 2024 Financial Results
From ImmunityBio, Inc.
Via Business Wire
News headline image
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? ↗
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
Topics Government
News headline image
Jeff Bezos Ends Washington Post's 36-Year Tradition Of Endorsements, Leaving Staff 'Roiled' ↗
The Washington Post is not endorsing a candidate in a presidential election for the first time since 1988. Sources say the decision came from Jeff Bezos. 
Via Benzinga
News headline image
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
From ImmunityBio, Inc.
Via Business Wire
News headline image
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio ↗
EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes. 
Via Benzinga
News headline image
Texas Instruments Posts Strong Q3 Results, Joins Valmont Industries, Lithia Motors, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
ImmunityBio to Participate in the Jefferies London Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
News headline image
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
News headline image
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Top 3 Health Care Stocks That Are Set To Fly This Quarter ↗
 
Via Benzinga
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024 ↗
IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.